JP2013504577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504577A5 JP2013504577A5 JP2012528860A JP2012528860A JP2013504577A5 JP 2013504577 A5 JP2013504577 A5 JP 2013504577A5 JP 2012528860 A JP2012528860 A JP 2012528860A JP 2012528860 A JP2012528860 A JP 2012528860A JP 2013504577 A5 JP2013504577 A5 JP 2013504577A5
- Authority
- JP
- Japan
- Prior art keywords
- par
- antigen
- binding fragment
- human
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 238000003776 cleavage reaction Methods 0.000 claims description 20
- 230000007017 scission Effects 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims description 8
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims description 8
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24078309P | 2009-09-09 | 2009-09-09 | |
| US61/240,783 | 2009-09-09 | ||
| US24282109P | 2009-09-16 | 2009-09-16 | |
| US61/242,821 | 2009-09-16 | ||
| US31783910P | 2010-03-26 | 2010-03-26 | |
| US61/317,839 | 2010-03-26 | ||
| PCT/US2010/048034 WO2011031695A1 (en) | 2009-09-09 | 2010-09-08 | High affinity human antibodies to human protease-activated receptor-2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015177339A Division JP6055055B2 (ja) | 2009-09-09 | 2015-09-09 | ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504577A JP2013504577A (ja) | 2013-02-07 |
| JP2013504577A5 true JP2013504577A5 (enExample) | 2013-09-05 |
| JP5832435B2 JP5832435B2 (ja) | 2015-12-16 |
Family
ID=43063654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528860A Expired - Fee Related JP5832435B2 (ja) | 2009-09-09 | 2010-09-08 | ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 |
| JP2015177339A Expired - Fee Related JP6055055B2 (ja) | 2009-09-09 | 2015-09-09 | ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015177339A Expired - Fee Related JP6055055B2 (ja) | 2009-09-09 | 2015-09-09 | ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8101724B2 (enExample) |
| EP (1) | EP2475684B1 (enExample) |
| JP (2) | JP5832435B2 (enExample) |
| KR (1) | KR101766701B1 (enExample) |
| CN (1) | CN102574923B (enExample) |
| AR (1) | AR078346A1 (enExample) |
| AU (1) | AU2010292342C1 (enExample) |
| BR (1) | BR112012005338A2 (enExample) |
| CA (1) | CA2773541A1 (enExample) |
| CY (1) | CY1118714T1 (enExample) |
| DK (1) | DK2475684T3 (enExample) |
| ES (1) | ES2609780T3 (enExample) |
| HR (1) | HRP20170324T1 (enExample) |
| HU (1) | HUE031725T2 (enExample) |
| IL (1) | IL218501A (enExample) |
| JO (1) | JO3246B1 (enExample) |
| LT (1) | LT2475684T (enExample) |
| MX (1) | MX2012002927A (enExample) |
| MY (1) | MY159551A (enExample) |
| NZ (1) | NZ599204A (enExample) |
| PL (1) | PL2475684T3 (enExample) |
| PT (1) | PT2475684T (enExample) |
| SG (1) | SG178976A1 (enExample) |
| SI (1) | SI2475684T1 (enExample) |
| SM (2) | SMT201700102T1 (enExample) |
| TW (1) | TWI492757B (enExample) |
| UY (1) | UY32883A (enExample) |
| WO (1) | WO2011031695A1 (enExample) |
| ZA (1) | ZA201201730B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| BR112014006822B1 (pt) * | 2011-09-22 | 2021-05-18 | Amgen Inc. | Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l |
| WO2015048245A1 (en) | 2013-09-25 | 2015-04-02 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| EP3110844B1 (en) * | 2014-02-28 | 2020-02-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| US10548987B2 (en) | 2015-07-31 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates for targeting CD56-positive tumors |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| EP3374386B1 (en) * | 2015-11-13 | 2024-05-29 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
| CN118480125A (zh) | 2016-11-08 | 2024-08-13 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
| TWI788332B (zh) * | 2017-03-16 | 2023-01-01 | 英商梅迪繆思有限公司 | 抗-par2抗體及其用途 |
| JOP20210194A1 (ar) * | 2019-01-18 | 2023-01-30 | Janssen Biotech Inc | مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CN114127109B (zh) * | 2019-05-30 | 2022-06-21 | 山东博安生物技术股份有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
| WO2021084760A1 (ja) * | 2019-11-01 | 2021-05-06 | 株式会社 資生堂 | 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤 |
| CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| EP4126248A4 (en) * | 2020-03-31 | 2024-07-10 | Fred Hutchinson Cancer Center | HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES |
| EP4454659A3 (en) | 2020-08-18 | 2025-01-22 | Cephalon LLC | Anti-par-2 antibodies and methods of use thereof |
| WO2023034560A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd33 and uses thereof |
| WO2023034564A2 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-cd33 antibodies and uses thereof |
| CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| WO2024059336A1 (en) * | 2022-09-18 | 2024-03-21 | Memorial Sloan Kettering Cancer Center | Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874400A (en) | 1993-07-26 | 1999-02-23 | Cor Therapeutics | Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| EP1500329B1 (en) * | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US7888482B2 (en) * | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| WO2008086069A1 (en) * | 2007-01-03 | 2008-07-17 | The General Hospital Corporation | Methods of treating itch |
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| KR20090082619A (ko) | 2008-01-28 | 2009-07-31 | 주식회사 알파크립텍 | 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물 |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| EP2313110A1 (en) | 2008-08-05 | 2011-04-27 | Boehringer Ingelheim International GmbH | Effectors of par-2 activation and their use in the modulation of inflammation |
| CN102458356A (zh) | 2009-06-18 | 2012-05-16 | 株式会社爱茉莉太平洋 | 含有栗子皮提取物的化妆料组合物 |
| KR101338681B1 (ko) | 2009-06-18 | 2013-12-09 | (주)아모레퍼시픽 | 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물 |
| FR2947452B1 (fr) | 2009-07-01 | 2012-04-20 | Fabre Pierre Dermo Cosmetique | L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau. |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
-
2010
- 2010-08-23 JO JOP/2010/0293A patent/JO3246B1/ar active
- 2010-09-07 AR ARP100103275A patent/AR078346A1/es unknown
- 2010-09-08 TW TW099130262A patent/TWI492757B/zh not_active IP Right Cessation
- 2010-09-08 SM SM20170102T patent/SMT201700102T1/it unknown
- 2010-09-08 HU HUE10754387A patent/HUE031725T2/en unknown
- 2010-09-08 WO PCT/US2010/048034 patent/WO2011031695A1/en not_active Ceased
- 2010-09-08 AU AU2010292342A patent/AU2010292342C1/en not_active Ceased
- 2010-09-08 JP JP2012528860A patent/JP5832435B2/ja not_active Expired - Fee Related
- 2010-09-08 CN CN201080047991.9A patent/CN102574923B/zh not_active Expired - Fee Related
- 2010-09-08 MY MYPI2012001005A patent/MY159551A/en unknown
- 2010-09-08 CA CA2773541A patent/CA2773541A1/en not_active Abandoned
- 2010-09-08 HR HRP20170324TT patent/HRP20170324T1/hr unknown
- 2010-09-08 MX MX2012002927A patent/MX2012002927A/es active IP Right Grant
- 2010-09-08 SG SG2012015228A patent/SG178976A1/en unknown
- 2010-09-08 US US12/877,133 patent/US8101724B2/en active Active
- 2010-09-08 EP EP10754387.8A patent/EP2475684B1/en active Active
- 2010-09-08 KR KR1020127008692A patent/KR101766701B1/ko not_active Expired - Fee Related
- 2010-09-08 PL PL10754387T patent/PL2475684T3/pl unknown
- 2010-09-08 NZ NZ599204A patent/NZ599204A/en not_active IP Right Cessation
- 2010-09-08 LT LTEP10754387.8T patent/LT2475684T/lt unknown
- 2010-09-08 SI SI201031386A patent/SI2475684T1/sl unknown
- 2010-09-08 PT PT107543878T patent/PT2475684T/pt unknown
- 2010-09-08 BR BR112012005338A patent/BR112012005338A2/pt not_active IP Right Cessation
- 2010-09-08 ES ES10754387.8T patent/ES2609780T3/es active Active
- 2010-09-08 DK DK10754387.8T patent/DK2475684T3/en active
- 2010-09-09 UY UY0001032883A patent/UY32883A/es not_active Application Discontinuation
-
2011
- 2011-12-14 US US13/325,098 patent/US8425907B2/en active Active
-
2012
- 2012-03-06 IL IL218501A patent/IL218501A/en not_active IP Right Cessation
- 2012-03-09 ZA ZA2012/01730A patent/ZA201201730B/en unknown
-
2013
- 2013-03-26 US US13/850,644 patent/US9028819B2/en active Active
-
2015
- 2015-09-09 JP JP2015177339A patent/JP6055055B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-01 CY CY20171100144T patent/CY1118714T1/el unknown
- 2017-02-15 SM SM201700102T patent/SMT201700102B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504577A5 (enExample) | ||
| CN103946240B (zh) | 对人ox40具有特异性的抗体分子 | |
| CN101379085B (zh) | Il-12/p40结合蛋白 | |
| JP6830533B2 (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| Smith et al. | Painful rheumatoid arthritis | |
| HRP20170324T1 (hr) | Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor | |
| CN110167963A (zh) | 治疗发炎病况的方法 | |
| TW200831533A (en) | Interleukin-13 binding proteins | |
| JP2014533279A5 (enExample) | ||
| JP2010043089A5 (enExample) | ||
| TW201233395A (en) | Methods for treating psoriasis | |
| TW201513883A (zh) | 治療牛皮癬的方法 | |
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| WO2013009521A9 (en) | Methods and compositions for treating asthma using anti-il-13 antibodies | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| EP3060250A1 (en) | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers | |
| Sibilia et al. | Rituximab: a new therapeutic alternative in rheumatoid arthritis | |
| KR20240052084A (ko) | 조합 및 이의 용도 | |
| McDermott | Rilonacept in the treatment of chronic inflammatory disorders | |
| AU2019269131B2 (en) | Antibodies against LIF and dosage forms thereof | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| WO2017011260A1 (en) | Treatment of pruritus | |
| US20160136272A1 (en) | Methods for restoring corticosteroid sensitivity | |
| Dimov et al. | Immunomodulators for asthma | |
| JP2023506779A (ja) | 慢性移植片対宿主病の処置用抗体 |